Loading…
Develops biologic therapies for cancer and rare diseases using multiple antibody engineering platforms.
Develops biologic therapies for cancer and rare diseases using multiple antibody engineering platforms.
Has no approved product, so it earns nothing from sales and is funded by cash raised from investors. It was formed in 2024 when Sanofi bought Inhibrx's alpha-1 antitrypsin programme, and the rest of the pipeline, led by its cancer antibody candidates, was spun off as a separate listed company.
Moat: none (IP / patents). Diversified biologics pipeline across multiple engineering platforms, but no approved products yet.
Headquarters: La Jolla, California, US · Founded: 2010 · Employees: 110
Size Inhibrx Biosciences (INBX) is a United States Health Care company (Biotechnology) with a market value of $1.24B, the 2115th largest of 3,117 United States companies the cockpit tracks. Shares closed at $84.52 on 6 Nov 2026.
Performance Over six months the shares fell 37.1%, against -13.1% for the median peer and -1.1% for the United States market (cap-weighted) — 4th lowest of 20 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +1.4%).
Short interest Short interest is 23.2% of the free float (15 Oct 2026).
Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $1.30M | $200,000 | $1.80M | $2.19M |
| Revenue growth | — | +550% | -89% | -18% | — |
| Gross profit | -$2.21M | -$1.18M | -$2.08M | $609,000 | n/a |
| EBITDA | -$126M | -$133M | -$329M | -$218M | -$128M |
| Net income | -$138M | -$140M | $1.69B | -$241M | -$145M |
| Free cash flow | -$132M | -$130M | -$197M | -$198M | -$116M |
| Capital expenditure | $10,000 | $31,000 | $2.60M | $4.59M | $686,000 |
| Total debt | $182M | $107M | $8.05M | $210M | $207M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Inhibrx Biosciences INBX | $1.24B | -37% | -100% | n/a | n/a | n/a |
| Grifols GRF.MC | $7.49B | +23% | 0% | 16% | 2.3× | 6.8% |
| Vertex Pharmaceuticals VRTX | $139B | +27% | +11% | 35% | 10.7× | 6.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INBX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.9% | -3.5% | 9th lowest of 21 |
| 6-month return | -37.1% | -13.1% | 4th lowest of 20 |
| Distance from 52-week high | -45.6% | -41.7% | 9th lowest of 21 |
| Revenue growth (TTM) | -100.0% | +1.4% | lowest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Inhibrx Biosciences INBX | United States | $1.24B | -37% | -100% | n/a | n/a | n/a | n/a |
| SpyGlass Pharma SGP | United States | $1.24B | +58% | n/a | n/a | n/a | n/a | n/a |
| Duality Biotherapeutics 9606.HK | Hong Kong | $1.23B | -60% | -5% | -181% | 7.0× | n/a | n/a |
| Akums Drugs and Pharmaceuticals AKUMS.NS | India | $1.22B | +34% | +18% | 10% | 2.1× | 15.8% | +9.9% |
| Vor Biopharma VOR | United States | $1.22B | +17% | n/a | n/a | n/a | n/a | n/a |
| COMPASS Pathways Plc Sponsored ADR CMPS | United States | $1.22B | -13% | n/a | n/a | n/a | n/a | n/a |
| UroGen Pharma URGN | United States | $1.21B | -16% | +159% | -12% | 5.2× | n/a | n/a |
| Liaoning Chengda Biotechnology 688739.SS | China | $1.28B | -10% | -9% | 0% | 2.5× | 8.8% | -7.0% |
| Rapport Therapeutics RAPP | United States | $1.17B | -36% | n/a | -838% | 39.3× | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 3.2× | 16.4% | -5.8% |
| Mineralys Therapeutics MLYS | United States | $1.36B | -48% | n/a | n/a | n/a | n/a | n/a |
| Pacific Shuanglin Bio-pharmacy 000403.SZ | China | $1.38B | -19% | +1% | 10% | 3.8× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.39B | +162% | +1,662% | -303% | 429.8× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.39B | -33% | +93% | 56% | 6.3× | -1.2% | +25.6% |
| Hualan Biological Vaccine 301207.SZ | China | $1.39B | -21% | -28% | -7% | 10.3× | 36.5% | -13.1% |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | 8.4× | 5.7% | -32.3% |
| Taysha Gene Therapies TSHA | United States | $1.41B | -36% | -32% | -2,855% | 184.6× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.41B | +43% | -13% | -359% | 743.5× | n/a | n/a |
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | 5.3× | n/a | n/a |
| Kardigan KARD | United States | $1.45B | n/a | n/a | n/a | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |